Small head circumference coupled with ApoE e4 gene is a factor in Alzheimer's disease

October 22, 2001

ST. PAUL, MN - The risk of developing Alzheimer's is increased for people with small head sizes who also carry an Alzheimer's-related gene, according to a study published in the October 23 issue of Neurology, the scientific journal of the American Academy of Neurology.

People with small head size and the gene variant apolipoprotein E e4 (ApoE e4) are 14 times more likely to develop Alzheimer's disease than people without that combination. Having a small head size without the gene did not significantly increase the risk of developing Alzheimer's.

This result adds weight to the theory that having a large "brain reserve" protects against Alzheimer's. Head circumference is one way to measure brain reserve.

"The theory is that the symptoms appear when the loss of brain cells goes below a critical threshold of brain reserve," said Amy Borenstein Graves, PhD, of the University of South Florida in Tampa, who conducted the study with researchers at the University of Washington in Seattle. "People with ApoE e4 are likely to have more rapid brain cell damage. Those with large brain reserves may have the same changes in their brains, but they don't show symptoms of the disease until much later."

The study involved 1,869 healthy Japanese Americans age 65 and older in King County, Washington. The study participants were followed for an average of 3.8 years. During that time, 59 people developed Alzheimer's disease.

The people who developed Alzheimer's were also older, less educated, shorter, lighter and had lower estimated verbal IQ (intelligence quotient) scores than those who did not develop Alzheimer's during the study period.

Borenstein Graves said that while brain growth is controlled in part by genetics, it may also be influenced by factors during the first 10 years of life such as malnutrition, poverty, infection, parental occupation and educational status, family size and birth order.

Later in life, factors such as higher education and income and mental and physical exercise may play a role in delaying the onset of Alzheimer's disease.

"It's interesting to speculate on whether we could prevent this disease if we could systematically boost our brain reserves throughout life," Borenstein Graves said. "In our study 18 percent of the risk of Alzheimer's was attributable solely to small head size. So if it were possible to increase brain reserve through prevention of brain damage that occurs across the life span, nearly 20 percent of the disease among these individuals might be preventable."

Study participants were divided into three groups, based on head circumference. Only the group with the smallest head circumference (less than 21.4 inches), and ApoE e-4, had a significantly greater risk of Alzheimer's.

Information on ApoE e-4 status was available for 59 percent of the study participants.

Borenstein Graves said a limitation of the study is its sample population of only Japanese Americans, which makes it difficult to apply the results to the general population.

"However, several studies with other populations have shown a relationship between head circumference and cognition and rates of developing Alzheimer's," she said.
-end-
For a copy of the study, contact Cheryl Alementi, 651-695-2737 calementi@aan.com

The study was supported by the National Institute on Aging.

The American Academy of Neurology, an association of more than 17,500 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. For more information about the American Academy of Neurology, visit its web site at www.aan.com.

American Academy of Neurology

Related Neurology Articles from Brightsurf:

Lancet Neurology publishes results of AFFiRiS' Phase 1 trial with PD01A in Parkinson's
AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology

Telemedicine effective for monitoring patients in large pediatric neurology network
As the COVID-19 pandemic sent entire communities into lockdown, doctors quickly adopted telehealth strategies without knowing whether they would be effective or feasible.

The Lancet Neurology: Discovery could speed diagnosis and treatment of children with life-threatening neurological diseases
A group of life-threatening neurological conditions affecting children have been linked to an antibody which points to potential treatment, according to an observational multicentre study involving 535 children with central nervous system (CNS) demyelinating disorders and encephalitis, published in The Lancet Neurology journal.

Meaningful change in culture urged to save neurology, reduce gender gap
UC Davis School of Medicine dean, NINDS deputy director lead national charge to improve conditions for women in neurology.

BrainStorm Cell Tx publishes NurOwn ALS Phase 2 randomized trial data in neurology
Results from Brainstorm Cell Therapeutic's NurOwn randomized Phase 2 clinical trial were published in Neurology.

The Lancet Neurology: Pioneering study suggests that an exoskeleton for tetraplegia could be feasible
A whole-body exoskeleton, operated by recording and decoding brain signals, has helped a tetraplegic patient to move all four of his paralysed limbs, according to results of a 2-year trial published in The Lancet Neurology journal.

The Lancet Neurology: Frailty could make people more susceptible to dementia
New research published in The Lancet Neurology journal suggests that frailty makes older adults more susceptible to Alzheimer's dementia, and moderates the effects of dementia-related brain changes on dementia symptoms.

The Lancet Neurology: Cannabis-based drug in combination with other anti-spasticity
Oral spray containing two compounds derived from the cannabis plant reduced spasticity compared with placebo in patients already taking anti-spasticity drugs.

New neurology studies a 'wakeup call' for global health
Neurology experts from around the world will convene Nov. 27 in New Zealand for a Global Brain Summit examining what one calls 'the greatest challenge of societies in the 21st century.' Among the neurological disorders to be discussed at the Summit are stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and migraine and other headaches.

The Lancet Neurology: Daily and weekly cycles of epileptic seizures more common than previously thought
Understanding the pattern of seizures, and how they are linked to circadian rhythms, could be important in improving management of epilepsy.

Read More: Neurology News and Neurology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.